First Trust Advisors
BLPH

First Trust Advisors’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

First Trust Advisors’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-20,515
Closed -$99K – 2714
2021
Q2 		$99K Sell
20,515
-723
-3% -$3.24K ﹤0.01% 2466
2021
Q1 		$110K Buy
21,238
+1,706
+9% +$11.9K ﹤0.01% 2399
2020
Q4 		$130K Sell
19,532
-883
-4% -$7.23K ﹤0.01% 2287
2020
Q3 		$208K Buy
+20,415
New +$240K ﹤0.01% 2231

Other funds holding BLPH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

First Trust Advisors's BLPH Position: Q3 2021 in Review

First Trust Advisors sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q3 2021, closing a stake of 20,515 shares — an estimated $99K sold.

First Trust Advisors first reported a position in BLPH in Q3 2020 and held it in 4 quarters. The position peaked at $208K in Q3 2020. 22 funds tracked by Wall St. Rank hold BLPH as of Q3 2021.

  • First Trust Advisors reported no remaining Bellerophon Therapeutics, Inc. position as of Q3 2021 after selling out during the quarter.
  • First Trust Advisors sold 20,515 Bellerophon Therapeutics, Inc. shares in Q3 2021, an estimated $99K.
  • First Trust Advisors first reported a position in Bellerophon Therapeutics, Inc. in Q3 2020 and held it in 4 quarters.
  • First Trust Advisors's Bellerophon Therapeutics, Inc. position peaked at $208K in Q3 2020.
  • 22 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q3 2021.

Based on First Trust Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.